Tempus
Tempus, Intermountain Healthcare Strike Precision Cancer Research Alliance
Intermountain will use Tempus' next-generation sequencing-based cancer assay to study patient samples to advance research into precision patient care.
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.
Aadi Bioscience Inks NGS Lab Partnerships to Screen Solid Tumor Patients for Fyarro Trial
The firm has partnered with Foundation Medicine, Tempus, and others to ID patients with TSC1 and TSC2 mutations for the Phase II PRECISION 1 clinical trial. Â
Tempus to Provide NGS Cancer Tests to US Department of Veterans Affairs
VA healthcare providers will be able to access Tempus' suite of next-generation sequencing-based cancer tests under a multiyear deal.
Tempus Submits PMA Application for Tumor Profiling Assay to FDA
The firm has submitted companion diagnostic and tumor profiling, and MSI status claims using DNA from FFPE tumor tissue and matched normal specimens.